In-hospital outcomes of percutaneous coronary intervention with drug-eluting stent in patients with localized and metastatic cancer.

Abstract

e18631 Background: Patients with localized and advanced malignancy are usually excluded from randomized clinical trials of drug-eluting stents and anti-platelet therapy. We aimed to evaluate short term outcomes of percutaneous coronary intervention (PCI) with drug-eluting stents (DES) in patients with localized and metastatic malignancy. Methods: Analysis from the Nationwide inpatient sample January 2016 to December 2018 of patients with localized and advanced malignancy admitted for a percutaneous coronary intervention with drug-eluting stents. Primary outcome was in-hospital mortality. Secondary outcomes were post-procedural complications and healthcare-utilization. Multivariate regression analysis was performed to adjust for confounders. Results: During 2016 – 2018 a total of weighted 1, 244, 550 PCI with DES were performed. 97.9 % in patients without cancer, 1.6% (n=21,125) patients with localized cancer and 0.3 % (n=4,765) with metastatic cancer. During hospitalization patient with cancer were more likely to develop respiratory failure, need for mechanical ventilation, AKI, and to receive blood products. After multivariate regression analysis patients with localized malignancy did not have any difference in-hospital mortality, total charges, cost, cardiac arrest or post procedural bleeding but had less LOS, respiratory failure, AKI requiring HD, post-procedural CVA and higher post-procedural blood transfusion when compared with patients without cancer. Conclusions: Patients with metastatic malignancy have higher in-hospital mortality when compared to patients without cancer. Patients with localized or advanced malignancy do not have higher in hospital complications. Blood transfusion is higher in patients with malignancy but is not related to procedure.[Table: see text]

Microenvironment-responsive electrocution of tumor and bacteria by implants modified with degenerate semiconductor film

“…Implants are widely used in both cases, they can fill the surgical site resulting from the tumor resection surgery [ 3 , 4 ]. Or as a stent to alleviate malignant obstruction in the palliative treatment [ 5 , 6 ]. For example, the golden strategy for osteosarcoma therapy is surgery to remove tumor tissues and fill the defects with implants; stents are widely used in palliation treatment of obstruction of trachea, bronchi, esophagus, and bile duct induced by various cancers.…”

Application of 3D printing technology in tumor diagnosis and treatment

“…An effective treatment is essential to improve the survival rate and quality of life of cancer patients. At present, cancer treatment mainly includes surgical resection, chemotherapy [19], radiotherapy [20], interventional therapy [21], immunotherapy [22], photothermal therapy [23], photodynamic therapy [24] and combined therapy [25]. Among them, surgical treatment directly removes the tumor, but it also has its limitations, such as the risk of an incomplete resection of the tumor, leading to its recurrence and metastasis, damage to healthy tissues and increased risk of infection [26].…”